Business
Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors
− Former Senior Vice President of the Oncology Business Unit at Genentech; Brings Over 25 Years of Extensive Leadership and Commercial Experience in the
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"− Former Senior Vice President of the Oncology Business Unit at Genentech; Brings Over 25 Years of Extensive Leadership and Commercial Experience in the Pharmaceutical Industry −\n\n\nNEWTON, Mass., Aug. 31, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Christy J. Oliger to its Board of Directors. Ms. Oliger is the former Senior Vice President of the Oncology Business Unit at Genentech, a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Ms. Oliger served in a wide variety of commercial leadership positions at Genentech from 2000 until 2020. Genentech is a member of the Roche Group, the world's largest biotech company and the global leader in cancer treatments and has been at the forefront of cancer research and treatment for over 50 years.\n\"Ms. Oliger is a pharmaceutical industry leader who brings broad commercial, portfolio management, and leadership experience having played a critical role in Genentech's significant commercial success over the past twenty years,\" said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. \"Her strategic expertise and counsel will be critical to Karyopharm as we continue to expand the global development and commercialization of XPOVIO® into different patient populations and potential new indications. On behalf of the Board of Directors and our executive leadership team, we welcome Ms. Oliger and look forward to her contributions.\"\nMs. Oliger brings over 25 years of biopharmaceutical industry experience, including various leadership roles in sales and marketing, portfolio management, and overseeing multiple business units at Genentech in oncology, rare diseases, neuroscience, and hematology. She was responsible for the U.S. oncology business unit and oncology pipeline, which generated over $13 billion of sales in 2019.\n\"It is a privilege to be joining Karyopharm's Board of Directors, especially as the company prepares to expand its reach into a variety of new patient populations with high unmet medical need,\" said Ms. Oliger. \"The therapeutic potential of XPOVIO is exciting given its innovative mechanism of action, oral administr...